The 2 American health care workers with Ebola were given a highly experimental treatment (3–4), previously tested on monkeys and never before given to humans, not even in small clinical trials. Some ask whether it is ethical to give such product to humans, especially those whose judgment may be clouded by desperate circumstances. Yet, when a patient's chances of dying exceed the chances of surviving, when significant symptoms have set in, and when recipients are health care workers whose potential to understand risks is probably high, such a decision seems more reasonable. These 2 patients have had the visibility of few other cases of public health, medical care, or research investigations. As such, experts from the Centers for Disease Control and Prevention, U.S. Food and Drug Administration, and National Institutes of Health probably weighed in on the pros and cons of releasing the experimental serum, and through such collective deliberation of experts some of the protections ordinarily provided to participants in research trials may have been realized.